• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • Experts on Demand
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Schizophrenia Therapeutics: A Market Briefing

$995.00 – $1,990.00

Clear
SKU: KLI1052647 Categories: Pharmaceuticals Market Research, Prescription Drugs Market Reports Pages: 54
  • Description
  • Table of Contents
  • Latest reports

Description

Schizophrenia is a life long affliction. There is no permanent cure for this illness. However, numerous drugs have made the effective management of the disease a reality.

This briefing examines both corrent and emerging therapeutic approaches for the management of schizophrenia. It provides an analysis of the current and future markets for these agents, including forecasts to 2009 segmented by geographic region and by type of drug and likely market scenarios for new agents not yet available. The briefing discusses the drugs currently in clinical trials, provides epidemiological information, and profiles the major competitors.

The information presented in this report is the result of primary and secondary research. Secondary research included data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. Primary research consisted of interviews and correspondance with company executives, clinicians, researchers and public health officials. The market forecasts are based on epidemiology, historical growth rates, probable product introductions, analyst expectations, and expert consensus.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Epidemiology
  • Management of Schizophrenia
  • Drugs in Development
  • Market Summary
  • World Market for Novel Antipsychotics
  • Scope and Methodology

CHAPTER TWO: INTRODUCTION

  • Schizophrenia
    • Symptoms
    • Economic Burden
    • Causes
  • Complications
    • Distorted Perceptions of Reality
    • Hallucinations and Illusions
    • Delusions
  • Incidence
  • Types

CHAPTER THREE: TREATMENT OPTIONS

  • Pharmacological Treatments
    • Relapse Management
    • Adherence
  • Non-Pharmacological Treatments
    • Psychosocial Treatments

  • CHAPTER FOUR: DRUGS IN CLINICAL TRIALS

    • Newer Treatment Approaches
    • Preclinical Agents
      • A320436
      • Dopamine D2 Partial Agonist Agent
      • ORG 25543
      • MEM 3454
      • Clera 120
    • Phase I Clinical Agents
      • LY 483518
      • SB 277011
      • MGS 0028
      • Muscarinic M1 Agonist Compound
      • SGS 518
      • Neboglamine
    • Phase II Clinical Agents
      • DAR 0100
      • Palindore
      • Reminertant
      • Lurasidone
      • Talnetant
    • Phase III Clinical Agents
      • Bifeprunox
      • Lonasen
      • Iloperidone

CHAPTER FIVE: MARKET FORECASTS

  • Opportunities and Drivers
  • World Market Breakdown
    • 5H2 and D2 Antagonist Antipsychotic Agents
    • Atypical Antipsychotic Agents
    • 5H1A and D2 Partial Agonist and D2 and D3 Antagonist Agents
    • Novel Antipsychotic Agents
    • Geographical Breakdown of Antipsychotic Agents

CHAPTER SIX: KEY PLAYERS

  • Astra Zeneca PLC
  • Abbott Laboratories
  • Johnson and Johnson
  • Novartis AG
  • Pfizer Inc.

LIST OF EXHIBITS

  • Exhibit 1: Schizophrenia Cases, Geographical Breakdown
  • Exhibit 2: Status of Key Late-Stage Antipsychotic Agents
  • Exhibit 3: World Market for Antipsychotics Summary 2004-2009
  • Exhibit 4: World Market for Antipsychotics by Geographic Segment Summary 2004-2009
  • Exhibit 5: World Market for Antipsychotics by Drug Type Summary 2004-2009
  • Exhibit 6: World Market for Novel Antipsychotics 2006-2009
  • Exhibit 7: Schizophrenia Cases, Geographical Breakdown
  • Exhibit 8: World Market for Antipsychotic Agents 2004-2009
  • Exhibit 9: Expected Launch Dates of Late Stage Antipsychotic Agents
  • Exhibit 10: World Market for Antipsychotics by Drug Type (5 H2 & D2 antagonists, atypical antipsychotics, 5 H1A & D2 partial agonist, D2 & D3 antagonists, and benzamides) 2004-2009
  • Exhibit 11: World Market for 5H2 and D2 Antagonist Segment
  • Exhibit 12: World Market for Atypical Antipsychotic Segment
  • Exhibit 13: World Market for 5H1A and D2 Partial Agonist Segment
  • Exhibit 14: World Market for D2 and D3 Antagonist Segment
  • Exhibit 15: World Market for Novel Antipsychotic Therapies 2006-2009
  • Exhibit 16: World Market for Antipsychotics by Geographic Segment (U.S., Europe, Japan, ROW) 2004-2009

 

    Cell and Gene Therapy Funding and Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2023
    December 8, 2023
    Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals
    May 22, 2023
    Precision Cancer Therapeutics Market, 2022
    October 25, 2022
    The World Market for Vaccines, 2022-2027
    September 23, 2022

Related products

  • Placeholder image

    Men’s Health: The World Market for Current and Emerging Drug Therapies

    $2,625.00 – $5,250.00
  • Placeholder image

    Worldwide Market for Prescription Dermatological Drugs – 4th Edition, The

    $3,500.00 – $7,000.00
  • Placeholder image

    Early Stage Drug Discovery 2004: Combi-chem & High Throughput Screening Revisited

    $2,995.00 – $5,990.00
  • Placeholder image

    U.S. Market for OTC Diet Aids, The

    $3,000.00 – $6,000.00

Contact Us

  •  Email Us: Customer Service

  •  Phone (US):  703-778-3080

  •  Fax:  703-778-3081

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • Global Medtech Sales Exceed $500 Billion as Chronic Diseases Shape Market’s Future November 14, 2023
  • Healthcare Advances, Investments Support Laboratory Information System (LIS) Growth October 26, 2023
  • Personalized Medicine Key to IVD Procedure Volumes’ 10% Annual Growth October 19, 2023
  • RNA Sequencing: Life Sciences’ Transformative $2.6 Billion Industry October 4, 2023
  • How Globalization and Climate Change Impact COVID-19 and the IVD Market September 20, 2023

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Direct-to-Consumer Pharmaceutical Marketing 2005: Controversies ContinueInformatics in Drug Discovery: The Evolving Information Technology Marketpl...
Scroll to top